Mcl-1 downregulation has already been shown to sensitize cholangiocarcinoma cells to TRAIL-induced apoptosis [23] and CML cells towards treatment with imatinib [24]. This evidence concerns the gene MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive.